Results 31 to 40 of about 241,371 (303)
Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
Cancer Cell International, 2018 Background Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters.
Shao-hsuan Wen +4 more
doaj +1 more source
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
BMC Cancer, 2008 Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei +9 more
doaj +1 more source
Molecular Medicine, 2021 Background Previous studies showed that doxorubicin could lead to osteoarthritis (OA) by inducing chondrocyte inflammation and apoptosis. Besides, it is reported that platelet-rich plasma (PRP) could suppress the activation of inflammatory NF-κB ...
Haijun Zhao +3 more
doaj +1 more source
BMC Cancer, 2012 Background Since proteins involved in chemotherapy drug pharmacokinetics and pharmacodynamics have a strong impact on the uptake, metabolism, and efflux of such drugs, they likely play critical roles in resistance to chemotherapy drugs in cancer patients.
Heibein Allan D +4 more
doaj +1 more source
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells [PDF]
, 2012 We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis ...
Dittmann, Kai +49 more
core +1 more source
, 2019 The development of elongated nanoparticles for drug delivery is of growing interest in recent years, due to longer blood circulation and improved efficacy compared to spherical counterparts.
Franco Dosio (93166) +17 more
core +1 more source
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency.
PLoS ONE, 2019 Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin, limits its continued therapeutic use.
Christina Schindler +7 more
doaj +1 more source
Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. [PDF]
PLoS ONE, 2013 The antineoplastic efficacy of anthracyclines is limited by their cardiac toxicity. In this study, we evaluated the toxicity of doxorubicin, non-pegylated liposomal-delivered doxorubicin, and epirubicin in HL-1 adult cardiomyocytes in culture as well as ...
Stefano Toldo +12 more
doaj +1 more source
Pharmaceutics, 2023 Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress.
Tanawat Attachaipanich +2 more
doaj +1 more source
Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells [PDF]
, 2009 BACKGROUND: Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics analysis of gene expression data was used to identify chemoresistance-associated changes in neuroblastoma biology.
Tatyana Suhan +41 more
core +1 more source